Journal of the American Academy of Dermatology · 2025
Decreased risk of cardiovascular disease in dermatology patients taking niacinamide: A TriNetX cohort study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salem Yousef, Liaqat Mahnoor, Gonna Nadeen, Zamil Dina, Abu-Ghosh Ferris, Merie Anwar, Cassimatis Dimitri, Orengo Ida
Аннотация
BACKGROUND: Niacinamide is frequently used for nonmelanoma skin cancer (NMSC) chemoprophylaxis. Recent studies raised concerns about cardiovascular risk associated with niacin metabolites.
OBJECTIVE: To evaluate the association between oral niacinamide use and cardiovascular outcomes in patients with multiple NMSCs.
METHODS: We conducted a retrospective cohort study using the TriNetX platform. Patients with ≥ 2 NMSCs or bullous pemphigoid who began taking oral niacinamide (≥ 500 mg) were matched 1:1 with niacinamide-naive controls. Outcomes included various major cardiovascular events.
RESULTS: After matching, each cohort consisted of 3231 patients. Niacinamide use was associated with reduced risk of ST elevation myocardial infarction (risk ratio [RR]: 0.547, 95% confidence interval [CI]: 0.349-0.858, P = .008), peripheral vascular disease (RR: 0.741, 95% CI: 0.605-0.909, P = .004), and cardiac arrest (RR: 0.500, 95% CI: 0.275-0.909, P = .020). Subgroup analyses by atherosclerotic cardiovascular disease history showed consistent cardiovascular benefits.
LIMITATIONS: As an observational study, causality cannot be established. The predominantly White study population and 3-year timeframe limit generalizability.
CONCLUSION: Niacinamide supplementation is associated with reductions in certain types of cardiovascular events, supporting its use in appropriate patient populations.
OBJECTIVE: To evaluate the association between oral niacinamide use and cardiovascular outcomes in patients with multiple NMSCs.
METHODS: We conducted a retrospective cohort study using the TriNetX platform. Patients with ≥ 2 NMSCs or bullous pemphigoid who began taking oral niacinamide (≥ 500 mg) were matched 1:1 with niacinamide-naive controls. Outcomes included various major cardiovascular events.
RESULTS: After matching, each cohort consisted of 3231 patients. Niacinamide use was associated with reduced risk of ST elevation myocardial infarction (risk ratio [RR]: 0.547, 95% confidence interval [CI]: 0.349-0.858, P = .008), peripheral vascular disease (RR: 0.741, 95% CI: 0.605-0.909, P = .004), and cardiac arrest (RR: 0.500, 95% CI: 0.275-0.909, P = .020). Subgroup analyses by atherosclerotic cardiovascular disease history showed consistent cardiovascular benefits.
LIMITATIONS: As an observational study, causality cannot be established. The predominantly White study population and 3-year timeframe limit generalizability.
CONCLUSION: Niacinamide supplementation is associated with reductions in certain types of cardiovascular events, supporting its use in appropriate patient populations.